CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
1.23
0.82%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.05
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026235 %
Charges from full value of position ($-4.98)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026235%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.004012 %
Charges from full value of position ($0.76)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.004012%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

OptiNose Inc ESG Risk Ratings

High Medium Low Negligible

‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 1.22
Open* 1.21
1-Year Change* -30.06%
Day's Range* 1.21 - 1.23
52 wk Range 0.90-2.07
Average Volume (10 days) 217.39K
Average Volume (3 months) 5.75M
Market Cap 137.02M
P/E Ratio -100.00K
Shares Outstanding 112.31M
Revenue 71.98M
EPS -0.39
Dividend (Yield %) N/A
Beta -0.16
Next Earnings Date Mar 5, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 1, 2023 1.23 0.02 1.65% 1.21 1.23 1.20
Nov 30, 2023 1.22 -0.01 -0.81% 1.23 1.24 1.20
Nov 29, 2023 1.22 0.03 2.52% 1.19 1.22 1.18
Nov 28, 2023 1.21 -0.01 -0.82% 1.22 1.22 1.18
Nov 27, 2023 1.18 -0.02 -1.67% 1.20 1.22 1.15
Nov 24, 2023 1.21 0.01 0.83% 1.20 1.22 1.20
Nov 22, 2023 1.20 0.03 2.56% 1.17 1.21 1.17
Nov 21, 2023 1.19 0.02 1.71% 1.17 1.21 1.14
Nov 20, 2023 1.15 -0.04 -3.36% 1.19 1.22 1.13
Nov 17, 2023 1.22 -0.01 -0.81% 1.23 1.24 1.20
Nov 16, 2023 1.22 0.02 1.67% 1.20 1.23 1.19
Nov 15, 2023 1.22 0.02 1.67% 1.20 1.23 1.19
Nov 14, 2023 1.22 0.00 0.00% 1.22 1.23 1.17
Nov 13, 2023 1.20 0.02 1.69% 1.18 1.25 1.18
Nov 10, 2023 1.19 -0.01 -0.83% 1.20 1.20 1.15
Nov 9, 2023 1.20 -0.09 -6.98% 1.29 1.29 1.20
Nov 8, 2023 1.21 0.02 1.68% 1.19 1.23 1.13
Nov 7, 2023 1.19 0.03 2.59% 1.16 1.19 1.14
Nov 6, 2023 1.16 -0.07 -5.69% 1.23 1.23 1.14
Nov 3, 2023 1.22 -0.01 -0.81% 1.23 1.24 1.19

OptiNose Events

Time (UTC) Country Event
Tuesday, March 5, 2024

Time (UTC)

13:30

Country

US

Event

Q4 2023 OptiNose Inc Earnings Release
Q4 2023 OptiNose Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 76.276 74.652 49.117 34.631 7.065
Revenue 76.276 74.652 49.117 34.631 7.065
Total Operating Expense 132.172 141.102 136.336 137.387 107.305
Selling/General/Admin. Expenses, Total 107.649 106.633 105.438 104.155 95.618
Research & Development 15.26 25.318 23.378 20.783 10.099
Operating Income -55.896 -66.45 -87.219 -102.756 -100.24
Interest Income (Expense), Net Non-Operating -17.541 -15.921 -12.566 -7.297 -6.824
Other, Net -1.396 0.075 0 0.406
Net Income Before Taxes -74.833 -82.296 -99.785 -110.053 -106.658
Net Income After Taxes -74.833 -82.296 -99.785 -110.053 -106.658
Net Income Before Extra. Items -74.833 -82.296 -99.785 -110.053 -106.658
Net Income -74.833 -82.296 -99.785 -110.053 -106.658
Total Adjustments to Net Income 0
Income Available to Common Excl. Extra. Items -74.833 -82.296 -99.785 -110.053 -106.658
Income Available to Common Incl. Extra. Items -74.833 -82.296 -99.785 -110.053 -106.658
Dilution Adjustment
Diluted Net Income -74.833 -82.296 -99.785 -110.053 -106.658
Diluted Weighted Average Shares 85.9001 56.8519 48.2752 41.8775 39.766
Diluted EPS Excluding Extraordinary Items -0.87116 -1.44755 -2.067 -2.62797 -2.68214
Dividends per Share - Common Stock Primary Issue 0
Diluted Normalized EPS -0.87116 -1.44755 -2.067 -2.45712 -2.68214
Cost of Revenue, Total 9.263 9.151 7.52 5.294 1.588
Gross Profit 67.013 65.501 41.597 29.337 5.477
Unusual Expense (Income) 0 7.155 0
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 19.454 11.845 20.856 20.078 20.582
Revenue 19.454 11.845 20.856 20.078 20.582
Cost of Revenue, Total 2.571 1.706 2.981 2.125 2.143
Gross Profit 16.883 10.139 17.875 17.953 18.439
Total Operating Expense 23.626 26.215 29.212 30.878 35.927
Selling/General/Admin. Expenses, Total 20.104 22.724 23.31 25.486 29.514
Research & Development 0.951 1.785 2.921 3.267 4.27
Operating Income -4.172 -14.37 -8.356 -10.8 -15.345
Interest Income (Expense), Net Non-Operating 6.798 -4.48 -5.397 -4.154 -4.052
Net Income Before Taxes 2.626 -18.85 -15.149 -14.954 -19.397
Net Income After Taxes 2.626 -18.85 -15.149 -14.954 -19.397
Net Income Before Extra. Items 2.626 -18.85 -15.149 -14.954 -19.397
Net Income 2.626 -18.85 -15.149 -14.954 -19.397
Income Available to Common Excl. Extra. Items 2.573 -18.797 -15.149 -14.954 -19.397
Income Available to Common Incl. Extra. Items 2.573 -18.797 -15.149 -14.954 -19.397
Diluted Net Income 2.573 -18.797 -15.149 -14.954 -19.397
Diluted Weighted Average Shares 112.042 111.96 95.06 83.3207 82.7401
Diluted EPS Excluding Extraordinary Items 0.02296 -0.16789 -0.15936 -0.17948 -0.23443
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS 0.02296 -0.16789 -0.15936 -0.17948 -0.23443
Gain (Loss) on Sale of Assets 0 0
Other, Net -1.396
Total Adjustments to Net Income -0.053 0.053
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 140.484 160.379 180.652 168.06 212.857
Cash and Short Term Investments 94.244 110.502 144.156 147.144 200.99
Cash & Equivalents 94.244 110.502 144.156 147.144 200.99
Total Receivables, Net 33.932 35.449 23.394 13.818 2.552
Accounts Receivable - Trade, Net 33.932 35.449 23.394 13.818 2.552
Prepaid Expenses 2.865 2.568 4.037 3.593 2.162
Total Assets 144.222 166.071 188.813 172.65 216.989
Property/Plant/Equipment, Total - Net 3.24 5.398 8.006 4.438 3.884
Property/Plant/Equipment, Total - Gross 7.805 9.681 11.792 6.685 5.035
Accumulated Depreciation, Total -4.565 -4.283 -3.786 -2.247 -1.151
Other Long Term Assets, Total 0.498 0.294 0.155 0.152 0.248
Total Current Liabilities 178.73 59.235 52.172 36.139 25.697
Accounts Payable 5.291 8.013 5.489 3.625 7.116
Accrued Expenses 44.864 51.222 46.683 32.514 18.421
Notes Payable/Short Term Debt 128.575 0 0 0 0
Other Current Liabilities, Total 0 0.16
Total Liabilities 200.846 187.843 182.025 111.067 98.378
Total Long Term Debt 0 126.418 125.202 74.531 72.5
Long Term Debt 0 126.418 125.202 74.531 72.5
Other Liabilities, Total 22.116 2.19 4.651 0.397 0.181
Total Equity -56.624 -21.772 6.788 61.583 118.611
Redeemable Preferred Stock
Preferred Stock - Non Redeemable, Net
Common Stock 0.111 0.082 0.053 0.046 0.041
Additional Paid-In Capital 628.242 588.288 534.585 489.565 436.554
Retained Earnings (Accumulated Deficit) -684.893 -610.061 -527.765 -427.98 -317.927
Other Equity, Total -0.084 -0.081 -0.085 -0.048 -0.057
Total Liabilities & Shareholders’ Equity 144.222 166.071 188.813 172.65 216.989
Total Common Shares Outstanding 111.493 82.2389 52.9459 41.2275 37.8026
Total Inventory 9.443 11.847 9.042 3.484 7.132
Other Current Assets, Total 0.013 0.023 0.021 0.021
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 98.62 103.61 112.171 140.484 100.931
Cash and Short Term Investments 66.845 71.311 83.928 94.244 61.08
Cash & Equivalents 66.845 71.311 83.928 94.244 61.08
Total Receivables, Net 21.373 22.128 16.979 33.932 26.616
Accounts Receivable - Trade, Net 21.373 22.128 16.979 33.932 26.616
Total Inventory 8.043 7.732 8.303 9.443 10.415
Prepaid Expenses 2.359 2.439 2.961 2.865 2.779
Other Current Assets, Total 0.041
Total Assets 101.407 106.068 114.925 144.222 105.27
Property/Plant/Equipment, Total - Net 0.882 0.723 0.722 3.24 0.901
Property/Plant/Equipment, Total - Gross 5.659 5.422 5.347 7.805 5.354
Accumulated Depreciation, Total -4.777 -4.699 -4.625 -4.565 -4.453
Other Long Term Assets, Total 1.905 1.735 2.032 0.498 3.438
Total Current Liabilities 163.981 164.299 166.303 178.73 177.795
Accounts Payable 5.006 6.482 6.244 5.291 8.403
Accrued Expenses 29.162 28.423 31.08 44.864 41.285
Notes Payable/Short Term Debt 129.813 129.394 128.979 128.575 128.107
Total Liabilities 179.022 175.728 188.71 200.846 178.686
Total Long Term Debt 0 0 0 0 0
Long Term Debt 0 0
Other Liabilities, Total 15.041 11.429 22.407 22.116 0.891
Total Equity -77.615 -69.66 -73.785 -56.624 -73.416
Common Stock 0.112 0.112 0.112 0.111 0.084
Additional Paid-In Capital 632.765 631.426 629.927 628.242 596.329
Retained Earnings (Accumulated Deficit) -710.408 -701.114 -703.74 -684.893 -669.745
Other Equity, Total -0.084 -0.084 -0.084 -0.084 -0.084
Total Liabilities & Shareholders’ Equity 101.407 106.068 114.925 144.222 105.27
Total Common Shares Outstanding 112.312 112.092 111.956 111.493 83.5205
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -74.833 -82.296 -99.785 -110.053 -106.658
Cash From Operating Activities -67.651 -76.935 -86.206 -90.815 -91.817
Cash From Operating Activities 0.532 0.646 1.456 1.108 0.539
Non-Cash Items 12.406 11.498 12.219 17.673 8.947
Changes in Working Capital -5.756 -6.783 -0.096 0.457 5.355
Cash From Investing Activities -0.063 -0.062 -0.546 -0.557 -1.69
Capital Expenditures -0.063 -0.167 -0.546 -0.557 -1.69
Cash From Financing Activities 51.436 43.32 83.81 37.529 59.579
Financing Cash Flow Items -0.298 -0.227 -0.883 -5.776 -6.617
Issuance (Retirement) of Stock, Net 51.18 43.179 88.275 45.888 66.196
Issuance (Retirement) of Debt, Net 0.554 0.368 -3.582 -2.583 0
Foreign Exchange Effects 0.007 0.013 -0.044 -0.003 0.064
Net Change in Cash -16.271 -33.664 -2.986 -53.846 -33.864
Cash Interest Paid 15.091 14.17 11.561 8.785 8.253
Other Investing Cash Flow Items, Total 0 0.105
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -18.847 -74.833 -59.684 -44.73 -25.333
Cash From Operating Activities -10.478 -67.651 -49.971 -32.473 -19.335
Cash From Operating Activities 0.072 0.532 0.4 0.256 0.119
Non-Cash Items 2.438 12.406 9.08 6.509 2.533
Changes in Working Capital 5.859 -5.756 0.233 5.492 3.346
Cash From Investing Activities 0 -0.063 -0.06 -0.05 -0.048
Capital Expenditures 0 -0.063 -0.06 -0.05 -0.048
Cash From Financing Activities 0.162 51.436 0.649 0.276 0.249
Financing Cash Flow Items -0.298 0 0.027 0
Issuance (Retirement) of Debt, Net 0.554
Foreign Exchange Effects 0 0.007 -0.012 0.003 -0.003
Net Change in Cash -10.316 -16.271 -49.394 -32.244 -19.137
Other Investing Cash Flow Items, Total 0 0 0
Issuance (Retirement) of Stock, Net 0.162 51.18 0.649 0.249 0.249
Cash Interest Paid 4.255
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Fidelity Management & Research Company LLC Investment Advisor 13.1892 14801306 -54172 2023-06-30 LOW
MVM Partners LLP Venture Capital 13.0145 14605263 300 2022-12-31 LOW
Great Point Partners, LLC Hedge Fund 7.8771 8839939 945203 2023-06-30 HIGH
Kruttschnitt (Theodore H III) Individual Investor 6.0734 6815789 2649613 2022-12-31
Rosalind Advisors, Inc. Hedge Fund 5.7341 6435000 6435000 2023-07-11 LOW
Acorn Bioventures L.P. Venture Capital 5.6775 6371463 6371463 2022-11-23 HIGH
Bleichroeder LP Investment Advisor 3.6045 4045132 0 2023-06-30 LOW
Kingdon Capital Management, L.L.C. Hedge Fund 3.2518 3649237 0 2023-06-30 HIGH
Velan Capital Investment Management LP Investment Advisor/Hedge Fund 3.2051 3596861 100000 2023-06-30 HIGH
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 3.2025 3593922 448541 2023-06-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 3.1602 3546526 2958022 2023-06-30 LOW
Medical Strategy GmbH Investment Advisor 2.8894 3242548 -911950 2023-05-31 MED
MFS Investment Management Investment Advisor/Hedge Fund 2.5362 2846183 -28747 2023-06-30 LOW
Nantahala Capital Management, LLC Hedge Fund 2.3896 2681667 1231667 2023-06-30 MED
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.2658 1420495 698450 2023-06-30 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 1.0967 1230713 1023560 2023-06-30 LOW
GMT Capital Corp. Hedge Fund 0.9897 1110702 1087414 2023-06-30 LOW
Rice Hall James & Associates, LLC Investment Advisor/Hedge Fund 0.8614 966723 194763 2023-06-30 LOW
Miller (Peter K) Individual Investor 0.7017 787415 252830 2023-04-18 LOW
Easterly Investment Partners LLC Investment Advisor 0.66 740641 5640 2023-03-31 MED

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

OptiNose Company profile

About OptiNose Inc

OptiNose, Inc. is a specialty pharmaceutical company that is focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists. The Company’s products candidates include XHANCE (fluticasone propionate) and ONZETRA Xsail. The Company's product, XHANCE (fluticasone propionate) nasal spray, 93 mcg, is therapeutic utilizing its proprietary exhalation delivery system (EDS) device that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and, if approved, chronic rhinosinusitis without nasal polyps. The Onzetra Xsail is a sumatriptan nasal powder and sells in the United States, Canada and Mexico.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, OptiNose Inc revenues increased 52% to $74.7M. Net loss decreased 18% to $82.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Stock-based Compensation in R&D decrease of 13% to $1.1M (expense), Stock-based Compensation in SGA decrease of 1% to $8.9M (expense).

Industry: Pharmaceuticals (NEC)

1020 Stony Hill Rd Ste 300
YARDLEY
PENNSYLVANIA 19067-5539
US

Income Statement

  • Annual
  • Quarterly

News

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

12:39, 30 November 2023

Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

EZ PI expected to drop further but speed of decline

08:16, 29 November 2023

A weaker Dollar drives gold higher

Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

13:49, 28 November 2023

Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

13:20, 28 November 2023

RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

13:04, 28 November 2023

Crude prices slide on OPEC+ uncertainty

Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

12:55, 28 November 2023
GBP

UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?

UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.

10:48, 21 November 2023

People also watch

Gold

2,072.25 Price
+1.760% 1D Chg, %
Long position overnight fee -0.0193%
Short position overnight fee 0.0111%
Overnight fee time 22:00 (UTC)
Spread 0.30

XRP/USD

0.63 Price
-0.220% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

BTC/USD

39,809.25 Price
+0.450% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

US100

16,001.20 Price
+0.470% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 7.0

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading